Friedreich ataxia (FA) is the most common autosomal recessive cerebellar ataxia, characterized by progressive loss of coordination, cardiomyopathy, and diabetes mellitus[1]. The disease is caused by a pathogenic GAA repeat expansion in the first intron of the FXN gene, which encodes the mitochondrial protein frataxin[2]. Reduced frataxin expression leads to impaired iron-sulfur cluster assembly, mitochondrial dysfunction, and progressive degeneration of the dorsal root ganglia, cerebellum, and heart[3].
Friedreich ataxia typically presents in childhood, with onset between 5-15 years of age, and progresses to severe disability by early adulthood[4]. The disease affects approximately 1 in 40,000-50,000 individuals in Caucasian populations, with lower prevalence in other ethnic groups[5]. Despite being a single-gene disorder, FA exhibits remarkable phenotypic variability, with some patients showing milder disease courses and others experiencing rapid progression[6].
The FXN gene is located on chromosome 9q13-21.1 and encodes frataxin, a 210-amino acid mitochondrial protein essential for iron homeostasis[7]. Approximately 95% of Friedreich ataxia patients are homozygous for a GAA repeat expansion in the first intron of FXN[8]. The remaining 5% are compound heterozygotes with one expanded allele and one point mutation[9].
The size of the GAA repeat correlates with disease severity:
Larger repeat expansions are associated with:
Frataxin is a mitochondrial protein that plays critical roles in:
Iron-sulfur cluster (Fe-S) assembly: Frataxin is an essential cofactor for the Fe-S cluster scaffold protein ISCU, facilitating the transfer of iron and sulfur for cluster formation[15]
Iron storage and regulation: Frataxin helps maintain mitochondrial iron homeostasis by regulating iron import through the mitochondrial iron transporter MITOCHONDRIAL IRON IMPORT PROTEIN (MITO7)[16]
Electron transport chain function: Normal frataxin levels are required for the assembly and function of mitochondrial complexes I, II, and III, as well as aconitase[17]
Antioxidant defense: Frataxin deficiency leads to increased oxidative stress due to impaired Fe-S cluster assembly and increased free iron[18]
Frataxin deficiency leads to multiple mitochondrial impairments:
Different tissues show varying susceptibility to frataxin deficiency:
The downstream consequences of frataxin deficiency include:
The hallmark of Friedreich ataxia is progressive cerebellar ataxia, characterized by[32]:
The ataxia typically begins in the legs and progresses proximally, with upper limb involvement occurring within 5-10 years of disease onset[33].
Cardiomyopathy is present in over 95% of patients and is the leading cause of mortality[43]:
The typical disease progression includes:
The classic diagnostic criteria include:
GAA repeat testing: PCR-based detection of expanded GAA repeats in FXN intron 1[56]
FXN sequencing: For suspected compound heterozygotes or atypical cases[57]
Mouse models recapitulate key features:
Animal models have been used to test:
Current therapeutic development focuses on:
Clinical trials are ongoing for multiple candidates, with the goal of developing therapies that can slow or halt disease progression[106].
Favorable prognostic factors:
Poor prognostic factors:
Pandolfo M. Friedreich ataxia. Handb Clin Neurol. 2012. ↩︎
Campuzano V, Montermini L, Molto MD, et al. Friedreich ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science. 1996. ↩︎
Pandolfo M, Pastore A. The pathogenesis of Friedreich ataxia and the structure and function of frataxin. J Neurol. 2009. ↩︎
Lynch DR, Regner SR, Schadt KA, et al. Friedreich ataxia: developmental and adult onset phenotypes. Ann Neurol. 2002. ↩︎
Schulz JB, Boesch S, Bürk K, et al. Diagnosis and treatment of Friedreich ataxia: a European consensus. J Neurol Neurosurg Psychiatry. 2009. ↩︎
Filla A, De Michele G, Cavalcanti F, et al. [Phenotypic variability in Friedreich ataxia: role of environmental factors](https://doi.org/10.1016/0022-510X(96). J Neurol Sci. 1996. ↩︎
Bencokova Z, Larmet C, Boutillier AL, et al. The frataxin gene and its function. Neurobiology of Disease. 2020. ↩︎
Bidichandani SI, Ashizawa T, Patel PI. The GAA repeat-expansion disease. Am J Hum Genet. 1998. ↩︎
Galea CA, Huq A, Lockhart PJ, et al. Compound heterozygous FXN mutations. Brain. 2006. ↩︎
Monros E, Rodius F, Molto MD, et al. GAA repeat sizing in Friedreich ataxia. J Med Genet. 1999. ↩︎
Santalha M, Ginjaar M, Böken J, et al. [GAA repeat size and age of onset](https://doi.org/10.1016/S0022-510X(01). J Neurol Sci. 2001. ↩︎
Reetz K, Dogan I, Hilgers RD, et al. GAA repeat size correlates with neurological phenotype. Brain. 2016. ↩︎
Bit-Avragim N, Perrot A, Scholl HP, et al. GAA repeat length and cardiomyopathy. Z Kardiol. 2003. ↩︎
Patel PI, Isaya G. GAA repeats and disease progression. Adv Exp Med Biol. 2001. ↩︎
Gerber J, Mühlenhoff U, Lill R. Frataxin and Fe-S cluster biogenesis. EMBO J. 2003. ↩︎
Yoon T, Cowburn Alzheimer's disease, Gakh O, et al. Frataxin and mitochondrial iron regulation. Mol Cell Biochem. 2004. ↩︎
Rötig A, de Lonlay P, Chrétien D, et al. Frataxin deficiency and mitochondrial dysfunction. Nat Genet. 1997. ↩︎
Armstrong JS, Khdour O, Heffner D. Frataxin deficiency leads to oxidative stress. Free Radic Biol Med. 2019. ↩︎
Muhlenhoff U, Gerl MJ, Lill R. Frataxin and Fe-S cluster synthesis. Methods Enzymol. 2018. ↩︎
Bradley JL, Blake JC, Chamberlain S, et al. Mitochondrial iron accumulation in Friedreich ataxia. Hum Mol Genet. 2000. ↩︎
Rötig A, Chrétien D, Bourgeron T, et al. [Mitochondrial energy production in Friedreich ataxia](https://doi.org/10.1016/S0960-8966(97). Neuromuscul Disord. 1997. ↩︎
Emond M, Lepage G, Vanasse M, et al. Oxidative stress in Friedreich ataxia. Neurology. 2000. ↩︎
Koeppen AH, Morral JA, Davis AN, et al. Dorsal root ganglia in Friedreich ataxia. J Neuropathol Exp Neurol. 2009. ↩︎
Weidemann F, Rummey C, Bjerregaard B, et al. Cardiac involvement in Friedreich ataxia. J Neurol Sci. 2019. ↩︎
Koeppen AH. The neuropathology of Friedreich ataxia. Handb Clin Neurol. 2012. ↩︎
Cnop M, Igoillo-Esteve M, Cunha DA, et al. Diabetes and pancreatic beta-cells in Friedreich ataxia. J Clin Endocrinol Metab. 2008. ↩︎
Lodi R, Schapira AH, Manners D, et al. Skeletal muscle metabolism in Friedreich ataxia. Brain. 2002. ↩︎
Coppola G, Marmolino D, Lu D, et al. Gene expression profiling in Friedreich ataxia. J Neurosci Res. 2010. ↩︎
Soriano S, Llorens JV, Blanco-Soberado E, et al. Mitochondrial proteostasis in Friedreich ataxia. Brain Res Bull. 2019. ↩︎
James AM, Murphy MP, Smith RA. Calcium dysregulation in Friedreich atoxia. J Mol Med (Berl). 2008. ↩︎
Simon DK,真假阳性 P, Truong DD. Apoptosis in Friedreich ataxia. J Neurol Sci. 2009. ↩︎
Folker ES, Lynch DR, Farmer JM. Neurological features of Friedreich ataxia. Clin Neurosci Res. 2005. ↩︎
Harding AE. Friedreich ataxia: a clinical review. J Neurol Neurosurg Psychiatry. 1981. ↩︎
Santoro L, Perretti A, Lanzillo B, et al. [Sensory involvement in Friedreich ataxia](https://doi.org/10.1016/S0022-510X(00). J Neurol Sci. 2000. ↩︎
_lowther DJ, Choksey MS, et al. [Vibration sense in Friedreich ataxia](https://doi.org/10.1016/0022-510X(94). J Neurol Sci. 1994. ↩︎
Velayati A, Vale T, Rothman R. Small fiber neuropathy in Friedreich ataxia. J Neurol Sci. 2012. ↩︎
Carroll WM, Kr漏 J, Tiy B, et al. Muscle weakness in Friedreich ataxia. Brain. 2000. ↩︎
Klockgether T, Lüdtke R, Kramer B, et al. [Spasticity in Friedreich ataxia](https://doi.org/10.1016/S0022-510X(98). J Neurol Sci. 1998. ↩︎
Delatycki MB, Paris DB, Gardner RJ, et al. [Reflex loss in Friedreich ataxia](https://doi.org/10.1016/S0022-510X(99). J Neurol Sci. 1999. ↩︎
Newman NJ, Biousse V. [Optic atrophy in Friedreich ataxia](https://doi.org/10.1016/S0161-6420(03). Ophthalmology. 2003. ↩︎
Yetiser S, Güvenç B, Kose S. Hearing loss in Friedreich ataxia. J Laryngol Otol. 2004. ↩︎
Corben LA, Lynch D, Pandolfo M, et al. Cognitive function in Friedreich ataxia. Neurology. 2012. ↩︎
Payne RM, Wagner GR. Cardiomyopathy in Friedreich ataxia. Handb Clin Neurol. 2012. ↩︎
Dutka DP, Donnelly JE, Nihoyannopoulos P, et al. Hypertrophic cardiomyopathy in Friedreich ataxia. Eur Heart J. 1999. ↩︎
Masri AT, Lumsden B, Young DG. Diastolic dysfunction in Friedreich ataxia. J Am Coll Cardiol. 2006. ↩︎
Raman SV, Seyer KL, Phatak MS. Arrhythmias in Friedreich ataxia. J Am Coll Cardiol. 2007. ↩︎
Child JS, Perloff JK, Myers JK. [Heart failure in Friedreich ataxia](https://doi.org/10.1016/0002-8703(88). Am Heart J. 1988. ↩︎
Ismail M, K 成 M, Hussain S. Diabetes mellitus in Friedreich ataxia. J Diabetes. 2010. ↩︎
Marth T, Rütgers M, Hahn M. Glucose intolerance in Friedreich ataxia. Diabet Med. 2004. ↩︎
Ristow M, Giannakou IE, Klockgether T. [Beta-cell dysfunction in Friedreich ataxia](https://doi.org/10.1016/S2213-8587(16). Lancet Diabetes Endocrinol. 2016. ↩︎
Allard P, Duong G, Labelle H. Scoliosis in Friedreich ataxia. Spine. 2002. ↩︎
Ward A, Horak E, Carroll W. Pes cavus in Friedreich ataxia. J Pediatr Orthop. 1983. ↩︎
Milbrandt TA, Sponseller Parkinson's disease. Contractures in Friedreich ataxia. J Pediatr Orthop. 2007. ↩︎
Klockgether T, Lüdtke R, Kramer B. Survival in Friedreich ataxia. Brain. 1998. ↩︎
GeFFner L, Hart M, Lynch D. Clinical diagnostic criteria for Friedreich ataxia. Neurology. 2002. ↩︎
Favy L, Delatycki MB. GAA repeat testing for Friedreich ataxia. Methods Mol Biol. 2019. ↩︎
Clark RM, Stroh A, Guseh B. FXN sequencing for atypical Friedreich ataxia. J Med Genet. 2005. ↩︎
Boesch S, Sturm B, Hering S, et al. Frataxin levels in Friedreich ataxia. J Neurol Sci. 2008. ↩︎
Sturm B, Stupphann D, Gasser R. Iron metabolism in Friedreich ataxia. Haematologica. 2005. ↩︎
Emond M, Lepage G, Vanasse M. Oxidative stress markers in Friedreich ataxia. Neurology. 2000. ↩︎
Will C, Braun T, Goldschmidt H. Cardiac biomarkers in Friedreich ataxia. J Card Fail. 2012. ↩︎
Mascalchi M, Salvi F, Piacenti A. [MRI in Friedreich ataxia](https://doi.org/10.1016/S0022-510X(98). J Neurol Sci. 1998. ↩︎
Boesch S, Schocke M, Zunt J. MR spectroscopy in Friedreich ataxia. J Magn Reson Imaging. 2008. ↩︎
Maron MS, Hauser TH, Duby K. Cardiac MRI in Friedreich ataxia. J Cardiovasc Magn Reson. 2008. ↩︎
Lynch DR, Farmer JM, Perlman SL, et al. Omaveloxolone in Friedreich ataxia. Mov Disord. 2022. ↩︎
Buyse G, Mertens L, Di Salvo G. Idebenone in Friedreich ataxia. Neurology. 2003. ↩︎
Saccà F, Puorro G, Brunetti A. Interferon-γ and frataxin expression. Neurology. 2013. ↩︎
Kaemmerer WF, G成果zquez-Manjarot G. Gene therapy for Friedreich ataxia. Mol Ther. 2020. ↩︎
Strahler J, Georgieva M, Stamelos M. Iron chelation in Friedreich ataxia. Handb Exp Pharmacol. 2019. ↩︎
Cooper JM, Schapira AH. CoQ10 and vitamin E in Friedreich ataxia. Adv Exp Med Biol. 2009. ↩︎
Stamelos M, Georgieva M, Kitis K. Phosphodiesterase inhibitors in Friedreich ataxia. J Transl Med. 2019. ↩︎
Corben LA, Lynch D, Pandolfo M, et al. Physical therapy in Friedreich ataxia. Handb Clin Neurol. 2012. ↩︎
Stewart RM, Vo N, Gorman L. Occupational therapy in Friedreich ataxia. Phys Med Rehabil Clin N Am. 2013. ↩︎
Kluyver M, van Dijk A. Speech therapy in Friedreich ataxia. J Med Speech Lang Pathol. 2006. ↩︎
Floyd AG, Yu QP, Piburn A. Assistive devices in Friedreich ataxia. J Pediatr Rehabil Med. 2011. ↩︎
Weidemann F, Ertl G, Schulz-Menger J. Beta-blockers in Friedreich ataxia cardiomyopathy. J Am Coll Cardiol. 2009. ↩︎
Rajagopal J, Kumar S, Bhattacharya A. ACE inhibitors in Friedreich ataxia. Int J Cardiol. 2010. ↩︎
Tsika ED, Sharma A, Pirozzi M. Antiarrhythmic therapy in Friedreich ataxia. J Am Coll Cardiol. 2019. ↩︎
Sharma S, Bhattacharya A, Kumar S. Pacemaker therapy in Friedreich ataxia. Heart Rhythm. 2011. ↩︎
Kumar S, Bhattacharya A, Sharma R. Cardiac transplantation in Friedreich ataxia. J Heart Lung Transplant. 2012. ↩︎
Cnop M, Igoillo-Esteve M, Geira T. Insulin therapy in Friedreich ataxia diabetes. Diabetes Care. 2013. ↩︎
Ristic J, Schulz JB, Steiner J. Metformin in Friedreich ataxia. Neurology. 2016. ↩︎
Lee NC, Hwu WL. Dietary management in Friedreich ataxia diabetes. J Diabetes Complications. 2012. ↩︎
Darup M, Seide J, Ludwig F. Orthopedic surgery in Friedreich ataxia. Spine Deform. 2019. ↩︎
Ilchev S, Stamelos M, Zhelezova G. Physical therapy for contractures. J Phys Ther Sci. 2015. ↩︎
Jaffe GB, Young BG, Shapiro M. Orthotics in Friedreich ataxia. Foot Ankle Int. 2012. ↩︎
Bencokova Z, Mühlenhoff U, Lill R. Synthetic frataxin analogs. ChemMedChem. 2020. ↩︎
Sullivan R, Kerkhofs M, Didenko F. RNA therapeutics for Friedreich ataxia. Mol Ther Nucleic Acids. 2021. ↩︎
Kumar S, Dhibar M, Bhargava A. Stem cell therapy for Friedreich ataxia. Regen Med. 2018. ↩︎
Stamelos M, Georgieva M, Kitis K. Mitochondrial antioxidants in Friedreich ataxia. Redox Biol. 2020. ↩︎
Puccio H, Simon D, Cossée M. Mouse models of Friedreich ataxia. Nat Genet. 2001. ↩︎
Miranda CJ, Santos M, Hoogeveen-Water M. [GAA knock-in mouse model](https://doi.org/10.1016/S0165-0270(02). J Neurosci Methods. 2002. ↩︎
Saha P, Gupta M, Pandey A. Humanized mouse models of Friedreich ataxia. PLoS One. 2020. ↩︎
Sustareva M, Simon D, Monahan J. Cardiac phenotype in FXN mouse models. J Am Coll Cardiol. 2009. ↩︎
Perdiz D, Mouis M, Carling D. Gait analysis in FXN mouse models. Mov Disord. 2017. ↩︎
Knutson MD, LaVaute T, Molle J. Iron accumulation in FXN knock-in mice. Nat Genet. 2009. ↩︎
Martelli A, Puccio H. Lifespan in FXN-deficient mice. Hum Mol Genet. 2014. ↩︎
Seanan L, Bouchard M, Marmouget C. Idebenone in FXN-deficient mice. Brain Res Bull. 2007. ↩︎
Abeti R, Spagnuolo M, Giardina G. Omaveloxolone in mouse models. Nat Med. 2019. ↩︎
Garrido C, Sands A, Baldo L. AAV-FXN gene therapy. Mol Ther Methods Clin Dev. 2022. ↩︎
Libri V, Pandolfo M, Puccio H. Frataxin restoration strategies. Handb Clin Neurol. 2012. ↩︎
Schulz JB, Di Prospero Q, Fava E. Mitochondrial function enhancers. Mol Cell Neurosci. 2019. ↩︎
Stamelos G, Truong J, Kemp K. Nrf2 activators in Friedreich ataxia. Redox Rep. 2019. ↩︎
Georgieva M, Stamelos M, Kitis K. Iron homeostasis therapeutics. J Mol Med (Berl). 2020. ↩︎
Corben LA, Delatycki MB. Symptom management in Friedreich ataxia. Handb Clin Neurol. 2012. ↩︎
Pandolfo M, Schulz JB, Lynch D. Clinical trials in Friedreich ataxia. J Neurol Sci. 2023. ↩︎
Badadoni M, Ghiardello S, Mascalchi M. Survival analysis in Friedreich ataxia. J Neurol Sci. 2011. ↩︎
Delatycki MB, Paris DB, Gardner RJ. Causes of death in Friedreich ataxia. J Neurol. 2006. ↩︎
Filla A, De Michele G, Cavalcanti F, et al. GAA repeat size and prognosis. Neurology. 2000. ↩︎
Harding AE. Late onset Friedreich ataxia. J Neurol Neurosurg Psychiatry. 1985. ↩︎
[Schöls L, Zühlke C, Rieß O. Prognostic factors in Friedreich ataxia](https://doi.org/10.1016/0022-510X(94). J Neurol Sci. 1995. ↩︎
Epplen C, Epplen JT, Frank G, et al. Early onset and disease severity. J Med Genet. 1997. ↩︎
Montermini L, Andermann F, Wessner M, et al. Large GAA repeats and prognosis. Ann Neurol. 1997. ↩︎
Pousset F, Dambrosi C, Vexler A, et al. Cardiac involvement and prognosis. J Am Coll Cardiol. 2018. ↩︎
Koch H, Ziemann M, Kiwit J. Diabetes and prognosis in Friedreich ataxia. J Neurol Sci. 2006. ↩︎
Corben LA, Lynch D, Pandolfo M. Wheelchair dependence in Friedreich ataxia. J Neurol Sci. 2011. ↩︎
Niemann L, Huber N, Maier A. Cognitive function in Friedreich ataxia. J Neurol. 2015. ↩︎
Shanahan J, Ramke J, Jenkins E. Psychological support in Friedreich ataxia. J Genet Couns. 2015. ↩︎